<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39324144</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1448780</StartPage><MedlinePgn>1448780</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1448780</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1448780</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Limited data are available describing the effects of SARS-CoV-2 breakthrough infections on the plasma proteome.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">PCR-positive SARS-CoV-2 patients, enrolled in a natural history study, underwent analysis of the plasma proteome. A prospective cohort of 66 unvaccinated and 24 vaccinated persons with different degrees of infection severity were evaluated acutely (within 40 days of symptom onset), and at three and ten months. Comparisons based on vaccination status alone and unsupervised hierarchical clustering were performed. A second cohort of vaccinated Omicron patients were evaluated acutely and at ten months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Acutely, unvaccinated patients manifested overexpression of proteins involved in immune and inflammatory responses, while vaccinated patients exhibited adaptive immune responses without significant inflammation. At three and ten months, only unvaccinated patients had diminished but sustained inflammatory (C3b, CCL15, IL17RE) and immune responses (DEFA5,TREM1). Both groups had underexpression of pathways essential for cellular function, signaling, and angiogenesis (AKT1, MAPK14, HSPB1) across phases. Unsupervised clustering, based on protein expression, identified four groups of patients with variable vaccination rates demonstrating that additional clinical factors influence the plasma proteome. The proteome of vaccinated Omicron patients did not differ from vaccinated pre-Omicron patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Vaccination attenuates the inflammatory response to SARS-CoV-2 infection across phases. However, at ten months after symptom onset, changes in the plasma proteome persist in both vaccinated and unvaccinated individuals, which may be relevant to post-acute sequelae of SARS-CoV-2 and other viral infections associated with post-acute infection syndromes.</AbstractText><CopyrightInformation>Copyright Â© 2024 Huapaya, Gairhe, Kanth, Tian, Demirkale, Regenold, Sun, Lynch, Luo, Forsberg, Dewar, Rehman, Li, Krack, Kuruppu, Aboye, Barnett, Strich, Davey, Childs, Chertow, Kovacs, Torabi-Parizi and Suffredini.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huapaya</LastName><ForeName>Julio A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gairhe</LastName><ForeName>Salina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanth</LastName><ForeName>Shreya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Office of Biostatistics Research, National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirkale</LastName><ForeName>Cumhur Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regenold</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Bioinformatics Resource, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Nicolas F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Renjie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Office of Biostatistics Research, National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, The George Washington University, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Alisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewar</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Virus Isolation and Serology Laboratory, Applied and Developmental Directorate, Frederick National Laboratory, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehman</LastName><ForeName>Tauseef</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Virus Isolation and Serology Laboratory, Applied and Developmental Directorate, Frederick National Laboratory, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Willy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krack</LastName><ForeName>Janell</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuruppu</LastName><ForeName>Janaki</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aboye</LastName><ForeName>Etsubdink A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Medstar Heart and Vascular Institute, Medstar Washington Hospital Center, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medstar Heart and Vascular Institute, Medstar Washington Hospital Center, Washington, DC, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strich</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davey</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Childs</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Transplantation Immunotherapy, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chertow</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torabi-Parizi</LastName><ForeName>Parizad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suffredini</LastName><ForeName>Anthony F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="Y">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">breakthrough infections</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">post-acute sequelae</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39324144</ArticleId><ArticleId IdType="pmc">PMC11422241</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1448780</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. . Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis. Lancet. (2023) 401(10385):1341â60. doi:Â 10.1016/S0140-6736(23)00461-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00461-0</ArticleId><ArticleId IdType="pmc">PMC10036128</ArticleId><ArticleId IdType="pubmed">36966780</ArticleId></ArticleIdList></Reference><Reference><Citation>Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. . Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. (2020) 11:11â24.e4. doi:Â 10.1016/j.cels.2020.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7264033</ArticleId><ArticleId IdType="pubmed">32619549</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. (2022) 102:1170â81. doi:Â 10.1038/s41374-022-00830-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-022-00830-7</ArticleId><ArticleId IdType="pmc">PMC9362039</ArticleId><ArticleId IdType="pubmed">35922478</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, et al. . Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. (2021) 2:100287. doi:Â 10.1016/j.xcrm.2021.100287</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100287</ArticleId><ArticleId IdType="pmc">PMC8091031</ArticleId><ArticleId IdType="pubmed">33969320</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li X, Wu Q, Wang X, Qin Z, Wang Y, et al. . Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge. Cell Death Dis. (2022) 13:235. doi:Â 10.1038/s41419-022-04674-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04674-3</ArticleId><ArticleId IdType="pmc">PMC8919172</ArticleId><ArticleId IdType="pubmed">35288537</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W, Altay O, Arif M, Edfors F, Doganay L, Mardinoglu A, et al. . Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. EBioMedicine. (2021) 74:103723. doi:Â 10.1016/j.ebiom.2021.103723</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103723</ArticleId><ArticleId IdType="pmc">PMC8626206</ArticleId><ArticleId IdType="pubmed">34844191</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoodsma M, de Nooijer AH, Grondman I, Gupta MK, Bonifacius A, Koeken V, et al. . Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19. Front Immunol. (2022) 13:1027122. doi:Â 10.3389/fimmu.2022.1027122</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1027122</ArticleId><ArticleId IdType="pmc">PMC9670186</ArticleId><ArticleId IdType="pubmed">36405747</ArticleId></ArticleIdList></Reference><Reference><Citation>Captur G, Moon JC, Topriceanu CC, Joy G, Swadling L, Hallqvist J, et al. . Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine. (2022) 85:104293. doi:Â 10.1016/j.ebiom.2022.104293</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104293</ArticleId><ArticleId IdType="pmc">PMC9515404</ArticleId><ArticleId IdType="pubmed">36182629</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kim H, Kim SY, Kim Y, Lee JS, Dan K, et al. . In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients. Sci Rep. (2020) 10:22418. doi:Â 10.1038/s41598-020-80120-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80120-8</ArticleId><ArticleId IdType="pmc">PMC7772338</ArticleId><ArticleId IdType="pubmed">33376242</ArticleId></ArticleIdList></Reference><Reference><Citation>HaljasmÃ¤gi L, Salumets A, Rumm AP, JÃ¼rgenson M, Krassohhina E, Remm A, et al. . Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. Sci Rep. (2020) 10:20533. doi:Â 10.1038/s41598-020-77525-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77525-w</ArticleId><ArticleId IdType="pmc">PMC7689507</ArticleId><ArticleId IdType="pubmed">33239683</ArticleId></ArticleIdList></Reference><Reference><Citation>Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. . Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat Commun. (2023) 14:3417. doi:Â 10.1038/s41467-023-38682-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38682-4</ArticleId><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="pubmed">37296110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanth SM, Huapaya JA, Gairhe S, Wang H, Tian X, Demirkale CY, et al. . Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19. Cell Rep Med. (2024) 5:101642. doi:Â 10.1016/j.xcrm.2024.101642</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2024.101642</ArticleId><ArticleId IdType="pmc">PMC11293333</ArticleId><ArticleId IdType="pubmed">38981485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. . Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. (2020) 26:1609â15. doi:Â 10.1038/s41591-020-1021-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1021-2</ArticleId><ArticleId IdType="pmc">PMC7809634</ArticleId><ArticleId IdType="pubmed">32747830</ArticleId></ArticleIdList></Reference><Reference><Citation>BabaÄiÄ H, Christ W, AraÃºjo JE, Mermelekas G, Sharma N, Tynell J, et al. . Comprehensive proteomics and meta-analysis of COVID-19 host response. Nat Commun. (2023) 14:5921. doi:Â 10.1038/s41467-023-41159-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41159-z</ArticleId><ArticleId IdType="pmc">PMC10516886</ArticleId><ArticleId IdType="pubmed">37739942</ArticleId></ArticleIdList></Reference><Reference><Citation>Huapaya JA, Higgins J, Kanth S, Demirkale CY, Gairhe S, Aboye EA, et al. . Vaccination ameliorates cellular inflammatory responses in SARS-coV-2 breakthrough infections. J Infect Dis. (2023) 228:46â58. doi:Â 10.1093/infdis/jiad045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad045</ArticleId><ArticleId IdType="pmc">PMC10304754</ArticleId><ArticleId IdType="pubmed">36801946</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. (2022) 28:1461â7. doi:Â 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. (2022) 28:911â23. doi:Â 10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward JH. Hierarchical grouping to optimize an objective function. JASA. (1963) 58:236â44. doi:Â 10.1080/01621459.1963.10500845</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1963.10500845</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank-based inverse normal transformation for quantitative trait analysis in genome-wide association studies. Biometrics. (2020) 76:1262â72. doi:Â 10.1111/biom.13214</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/biom.13214</ArticleId><ArticleId IdType="pmc">PMC8643141</ArticleId><ArticleId IdType="pubmed">31883270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. (2019) 10:1523. doi:Â 10.1038/s41467-019-09234-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>KrÃ¤mer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. (2014) 30:523â30. doi:Â 10.1093/bioinformatics/btt703</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yogo Y, Fujishima S, Inoue T, Saito F, Shiomi T, Yamaguchi K, et al. . Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respir Res. (2009) 10:80. doi:Â 10.1186/1465-9921-10-80</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-10-80</ArticleId><ArticleId IdType="pmc">PMC2741459</ArticleId><ArticleId IdType="pubmed">19715610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Chen Y, Xia H, Wang C, Tan CY, Cai X, et al. . Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. Proc Natl Acad Sci U S A. (2020) 117:28336â43. doi:Â 10.1073/pnas.2018030117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2018030117</ArticleId><ArticleId IdType="pmc">PMC7668053</ArticleId><ArticleId IdType="pubmed">33082228</ArticleId></ArticleIdList></Reference><Reference><Citation>Toufiq M, Roelands J, Alfaki M, Syed Ahamed Kabeer B, Saadaoui M, Lakshmanan AP, et al. . Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. Immunology. (2020) 161:291â302. doi:Â 10.1111/imm.13239</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13239</ArticleId><ArticleId IdType="pmc">PMC7692248</ArticleId><ArticleId IdType="pubmed">32682335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar Deshmukh F, Yaffe D, Olshina MA, Ben-Nissan G, Sharon M. The contribution of the 20S proteasome to proteostasis. Biomolecules. (2019) 9(5):190. doi:Â 10.3390/biom9050190</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9050190</ArticleId><ArticleId IdType="pmc">PMC6571867</ArticleId><ArticleId IdType="pubmed">31100951</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Khoramjoo M, Srinivasan K, Gordon PMK, Mandal R, Jackson D, et al. . Sequential multi-omics analysis identifies clinical phenotypes and predictive biomarkers for long COVID. Cell Rep Med. (2023) 4:101254. doi:Â 10.1016/j.xcrm.2023.101254</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101254</ArticleId><ArticleId IdType="pmc">PMC10694626</ArticleId><ArticleId IdType="pubmed">37890487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SH, Ju HJ, Han JH, Lee JH, Lee W-S, Bae JM, et al. . Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open. (2023) 6:e2336120âe. doi:Â 10.1001/jamanetworkopen.2023.36120</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.36120</ArticleId><ArticleId IdType="pmc">PMC10559181</ArticleId><ArticleId IdType="pubmed">37801317</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng K, Li X, Yang D, Chan SCW, Zhou J, Wan EYF, et al. . Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine. (2023) 63:102154. doi:Â 10.1016/j.eclinm.2023.102154</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102154</ArticleId><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hileman CO, Malakooti SK, Patil N, Singer NG, McComsey GA. New-onset autoimmune disease after COVID-19. Front Immunol. (2024) 15:1337406. doi:Â 10.3389/fimmu.2024.1337406</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1337406</ArticleId><ArticleId IdType="pmc">PMC10883027</ArticleId><ArticleId IdType="pubmed">38390319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. . Longitudinal cytokine profile in patients with mild to critical COVID-19. Front Immunol. (2021) 12:763292. doi:Â 10.3389/fimmu.2021.763292</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.763292</ArticleId><ArticleId IdType="pmc">PMC8685399</ArticleId><ArticleId IdType="pubmed">34938289</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova ZR, Arsentieva NA, Liubimova NE, Batsunov OK, Dedkov VG, Gladkikh AS, et al. . Cytokine profiling in different SARS-coV-2 genetic variants. Int J Mol Sci. (2022) 23(22):14146. doi:Â 10.3390/ijms232214146</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214146</ArticleId><ArticleId IdType="pmc">PMC9692520</ArticleId><ArticleId IdType="pubmed">36430621</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova ZR, Arsentieva NA, Totolian AA. Macrophage-derived chemokine MDC/CCL22: an ambiguous finding in COVID-19. Int J Mol Sci. (2023) 24(17):13083. doi:Â 10.3390/ijms241713083</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241713083</ArticleId><ArticleId IdType="pmc">PMC10487728</ArticleId><ArticleId IdType="pubmed">37685890</ArticleId></ArticleIdList></Reference><Reference><Citation>Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, et al. . The role of the th2 CC chemokine ligand CCL17 in pulmonary fibrosis1. J Immun. (2004) 173:4692â8. doi:Â 10.4049/jimmunol.173.7.4692</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.7.4692</ArticleId><ArticleId IdType="pubmed">15383605</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium TU. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. (2022) 51:D523âD31. doi:Â 10.1093/nar/gkac1052</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1052</ArticleId><ArticleId IdType="pmc">PMC9825514</ArticleId><ArticleId IdType="pubmed">36408920</ArticleId></ArticleIdList></Reference><Reference><Citation>Born G, Breuer D, Wang S, Rohlmann A, Coulon P, Vakili P, et al. . Modulation of synaptic function through the Î±-neurexin-specific ligand neurexophilin-1. Proc Natl Acad Sci U S A. (2014) 111:E1274â83. doi:Â 10.1073/pnas.1312112111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312112111</ArticleId><ArticleId IdType="pmc">PMC3977266</ArticleId><ArticleId IdType="pubmed">24639499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>